Prognostic Role of PD-L1 in Malignant Pleural Mesothelioma: Unraveling the Complexity of the Tumor Microenvironment in Mesothelioma

Our plain-English summary of Prognostic Role of PD-L1 in Malignant Pleural Mesothelioma: Unraveling the Complexity of the Tumor Microenvironment in Mesothelioma, by M. de Perrot (The Annals of Thoracic Surgery, 2021).

The study

• Author: M. de Perrot
• Journal: The Annals of Thoracic Surgery
• Published: 2021;112(5):1583-1584
• Type of article: Comment
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher

In plain English

This article is an invited commentary, not an original study. It comments on a separate study by Lee and colleagues on PD-L1, a protein that can be present on tumor cells, in malignant pleural mesothelioma (MPM). The commentary reports that Lee and colleagues found high PD-L1 expression, meaning PD-L1 in 50% or more of tumor cells, was associated with worse survival in both epithelial and non-epithelial mesothelioma. In patients treated with complete macroscopic resection, that study saw high PD-L1 in 50% of sarcomatoid and 14% of epithelial mesothelioma. The study's gene analysis linked high PD-L1 to genes related to T cell exhaustion. The author compared these results with other published work on 'hot' mesotheliomas that carry a poor prognosis. The author suggested that these tumors are most likely the ones responding to combined ipilimumab and nivolumab, and stated that such patients should receive immunotherapy rather than upfront chemotherapy or surgery. The author concluded that ongoing study of the tumor microenvironment is gradually unraveling the disease. Asbestos is not discussed.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Invited commentary on another group's study (Lee and colleagues); no original data
• Who was studied: No population studied by this author. The commented-on study by Lee and colleagues looked at patients with malignant pleural mesothelioma treated with complete macroscopic resection. Patient numbers are not given in the commentary.
• Exposure: No asbestos exposure is discussed. The factor discussed is PD-L1 expression on mesothelioma tumor cells.
• Main results:
  • As reported by the commentary from Lee and colleagues' study: high PD-L1 expression (in 50% or more of tumor cells) was associated with worse survival in both epithelial and non-epithelial histology.
  • As reported from Lee and colleagues' study: high PD-L1 expression was seen in 50% of sarcomatoid and 14% of epithelial mesothelioma treated with complete macroscopic resection.
  • As reported from Lee and colleagues' study: gene pathway analysis associated high PD-L1 expression with genes related to T cell exhaustion and other immune pathways.
  • The author's view, drawing on other published studies: 'hot' MPM tumors are most likely those responding to ipilimumab-nivolumab, and such patients should be treated with immunotherapy rather than upfront chemotherapy or surgery.
• The authors' conclusion: The author concluded that new studies and ongoing analysis of the tumor microenvironment are progressively unraveling mesothelioma and opening new treatment possibilities.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: PD-L1, Pleural Mesothelioma, Tumor Microenvironment, Mesothelioma.

Related studies

• Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients — N. Fusco, V. Vaira, et al. (2020)
• Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma — N.S. Patil, L. Righi, et al. (2018)
• Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma — A.N. Qualiotto, C.M. Baldavira, et al. (2023)
• Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment — M. Zhang, J.L. Luo, et al. (2021)
• Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma — I.C. Salaroglio, J. Kopecka, et al. (2019)
• Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment — S. Judge, P. Thomas, et al. (2016)

Browse more research in The Annals of Thoracic Surgery, or return to medical research.